Patogeneza zapaleń dużych tętnic jako przykład powiązań wrodzonej i nabytej odpowiedzi immunologicznej – opis przypadku i przegląd literatury

• Authors: Marcin Milchert , Marek Brzosko

Title variants

EN

Pathogenesis of large vessel vasculitis as an example of innate and adaptive immunity relations – case report and literature review

• Languages of publication: PL EN

Abstracts

PL

Zapalenia dużych naczyń, czyli olbrzymiokomórkowe zapalenie tętnic (GCA) i choroba Takayasu (TAK), łączą komponenty autoimmunologiczne i autozapalne w stopniu zależnym od przewagi nabytej lub wrodzonej odpowiedzi immunologicznej. W GCA obie składowe mogą występować łącznie, samodzielnie lub też sekwencyjnie. Polimialgia reumatyczna jest chorobą ze spektrum GCA związaną z nadmierną aktywnością głównie odpowiedzi wrodzonej. Bywa ona uważana za formę „vasculitis sine vasculitis”. W TAK tradycyjnie wymienia się składowe trójfazowego przebiegu choroby: od niespecyficznej reakcji zapalnej do limfocytowych nacieków ściany tętnic prowadzących do ich uszkodzenia. Artykuł przybliża podstawy patogenezy zapaleń du- żych naczyń, podkreślając połączenia między komponentami odporności nabytej i wrodzonej, odpowiedzialne za niejednorodny obraz kliniczny tych chorób. Przedstawia także praktyczne wnioski kliniczne płynące ze zrozumienia patogenezy

EN

Large vessel vasculitis that include giant cell arteritis (GCA) and Takayasu arteritis (TAK), combine autoimmune and autoinflammatory components to a degree that depends on acquired or innate immune response involvement. In GCA, both components may occur together, independently or sequentially. Polymyalgia rheumatica is a part of GCA-disease spectrum mainly associated with innate immune response hyperactivity. It is sometimes considered to be a form of “vasculitis sine vasculitis”. In TAK there are three-phases of the disease traditionally described: from non-specific inflammatory reaction to lymphocytic infiltration of arterial walls leading to their destruction. This article outlines the basics of pathogenesis of large vessel vasculitis, highlighting the links between acquired and innate immunity responsible for the heterogeneous clinical picture of these diseases. It also presents practical clinical implications of understanding pathogenesis.

Keywords

EN

choroba Takayasu; olbrzymiokomórkowe zapalenie tętnic; patogeneza

Discipline

• MEDICINE: MEDICINE

• Publisher: Oficyna Wydawnicza Mediton
• Journal: Alergia Astma Immunologia - przegląd kliniczny
• Year: 2018
• Volume: 23
• Issue: 1
• Pages: 29-34

Contributors

author

Marcin Milchert

• Klinika Reumatologii, Chorób Wewnętrznych i Geriatrii Pomorskiego Uniwersytetu Medycznego w Szczecinie

author

Marek Brzosko

• Klinika Reumatologii, Chorób Wewnętrznych i Geriatrii Pomorskiego Uniwersytetu Medycznego w Szczecinie

References

• 1. Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med 2003; 139: 505-15.
• 2. Doria A, Zen M, Bettio S, et al. Autoinflammation and autoimmunity: bridging the divide. Autoimmun Rev 2012; 12: 22-30.
• 3. Keser G, Aksu K, Direskeneli H. Discrepancies between vascular and systemic inflammation in large vessel vasculitis: an important problem revisited. Rheumatology (Oxford). 2017 Sep 7, doi: 10.1093/ rheumatology/kex333 (w druku).
• 4. Salvarani C, Pipitone N, Boiardi L, et al. Do we need treatment with tumour necrosis factor blockers for giant cell arteritis? Ann Rheum Dis 2008; 67: 577-9.
• 5. Weyand CM, Hicok KC, Hunder GG, et al. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994; 121: 484-91.
• 6. Weyand CM, Tetzlaff N, Björnsson J, et al. Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum. 1997; 40: 19-26.
• 7. Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med 2003; 349: 160-9.
• 8. Pryshchep O, Ma-Krupa W, Younge BR, et al. Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation 2008; 118: 1276-84.
• 9. Weyand CM, Goronzy JJ. Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol 2013; 9: 731-40.
• 10. Milchert M, Brzosko M. Comment on "Polymyalgia rheumatica as the manifestation of unclassified aortitis". Mod Rheumatol 2008; 18: 427-8.
• 11. Brack A, Geisler A, Martinez-Taboada VM, et al. Giant cell vasculitis is a T cell-dependent disease. Mol Med 1997; 3: 530-43.
• 12. Martinez-Taboada V, Brack A, Hunder GG, et al. The inflammatory infiltrate in giant cell arteritis selects against B lymphocytes. J Rheumatol 1996; 23: 1011-1014.
• 13. Pache M, Kaiser HJ, Haufschild T, et al. Increased endothelin-1 plasma levels in giant cell arteritis: a report on four patients. Am J Ophthalmol. 2002; 133: 160-2.
• 14. Brouns K, Verbeken E, Degreef H, Bobbaers H, Blockmans D. Fatal calciphylaxis in two patients with giant cell arteritis. Clin Rheumatol 2007; 26: 836-40.
• 15. O'Brien JP, Regan W. Actinically degenerate elastic tissue is the likely antigenic basis of actinic granuloma of the skin and of temporal arteritis. J Am Acad Dermatol 1999; 40: 214-22.
• 16. Borchers AT, Gershwin ME. Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment. Autoimmun Rev 2012; 11: A544-A554.
• 17. Wilkinson IM, Russell RW. Arteries of the head and neck in giant cell arteritis. A pathological study to show the pattern of arterial involvement. Arch Neurol 1972; 27: 378-91.
• 18. Cid MC, Hernández-Rodríguez J, Esteban MJ, et al. Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis. Circulation 2002; 106: 1664-71.
• 19. Hoffman GS. Giant Cell Arteritis. Ann Intern Med 2016; 165: ITC- 65-ITC80.
• 20. Diaz VA, DeBroff BM, Sinard J. Comparison of histopathologic features, clinical symptoms, and erythrocyte sedimentation rates in biopsy-positive temporal arteritis. Ophthalmology 2005; 112: 1293-8.
• 21. Samson M, Corbera-Bellalta M, Audia S, et al. Recent advances in our understanding of giant cell arteritis pathogenesis. Autoimmun Rev 2017; 16: 833-44.
• 22. Rodríguez-Pla A, Bosch-Gil JA, Rosselló-Urgell J, et al. Metalloproteinase-2 and -9 in giant cell arteritis: involvement in vascular remodeling. Circulation 2005; 112: 264-9.
• 23. Eberhardt RT, Dhadly M. Giant cell arteritis: diagnosis, management, and cardiovascular implications. Cardiol Rev 2007; 15: 55-61.
• 24. Goodwin JS. Progress in gerontology: polymyalgia rheumatica and temporal arteritis. J Am Geriatr Soc 1992;. 40: 515-25.
• 25. Ly KH, Régent A, Tamby MC, et al. Pathogenesis of giant cell arteritis: More than just an inflammatory condition? Autoimmun Rev 2010; 9: 635-45.
• 26. Flores-Domínguez C, Hernández-Pacheco G, et al. Alleles of the major histocompatibility system associated with susceptibility to the development of Takayasu's arteritis. Gac Med Mex 2002; 138: 177- 83.
• 27. Arnaud L, Haroche J, Mathian A, et al. Pathogenesis of Takayasu's arteritis: a 2011 update. Autoimmun Rev 2011; 11: 61-7.
• 28. Yagi K, Kobayashi J, Yasue S, et al. Four unrelated cases with Takayasu arteritis and CD36 deficiency: possible link between these disorders. J Intern Med 2004; 255: 688-9.
• 29. Aggarwal A, Chag M, Sinha N, et al. Takayasu's arteritis: role of Mycobacterium tuberculosis and its 65 kDa heat shock protein. Int J Cardiol 1996; 55: 49-55.
• 30. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65: 1-11.
• 31. Chen ZW, Symons SP, Young B, et al. A 24-year-old male with headaches. Brain Pathol 2010; 20: 863-6.
• 32. Grishman E. Disseminated giant cell arteritis. Mod Pathol 1993; 6: 633-6.
• 33. Morris CR, Scheib JS. Fatal myocardial infarction resulting from coronary arteritis in a patient with polymyalgia rheumatica and biopsy-proved temporal arteritis. A case report and review of the literature. Arch Intern Med 1994; 154: 1158-60.
• 34. Katz-Agranov N, Tanay A, Bachar DJ, et al. What to do when the Diagnosis of Giant Cell Arteritis and Takayasu's Arteritis Overlap. Isr Med Assoc J 2015; 17: 123-5.
• 35. Navarro M, Cervera R, Font J, et al. Anti-endothelial cell antibodies in systemic autoimmune diseases: prevalence and clinical significance. Lupus 1997; 6: 521-6.
• 36. McCarthy EM, MacMullan PA, Al-Mudhaffer S, et al. Plasma fibrinogen is an accurate marker of disease activity in patients with polymyalgia rheumatica. Rheumatology (Oxford) 2013; 52: 465-71.
• 37. van der Geest KS, Abdulahad WH, Rutgers A, et al. Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica. Rheumatology (Oxford) 2015; 54: 1397-402.
• 38. Goronzy JJ, Weyand CM. Cytokines in giant-cell arteritis. Cleve Clin J Med 2002; 69: SII91-SII94.
• 39. Cutolo M, Montecucco CM, Cavagna L, et al. Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1438-43.
• 40. García-Martínez A, Hernández-Rodríguez J, Espígol-Frigolé G, et al. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term follow up of patients with giant cell arteritis. Arthritis Care Res (Hoboken) 2010; 62: 835-41.
• 41. Aschwanden M, Kesten F, Stern M, et al. Vascular involvement in patients with giant cell arteritis determined by duplex sonography of 2x11 arterial regions. Ann Rheum Dis 2010; 69: 1356-9.
• 42. Deng J, Younge BR, Olshen RA, et al. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 2010; 121: 906-15.
• 43. Seyahi E, Ucgul A, Cebi Olgun D, et al. Aortic and coronary calcifications in Takayasu arteritis. Semin Arthritis Rheum 2013; 43: 96-104.
• 44. Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007; 56: 2789-97.
• 45. Loock J, Henes J, Kötter I, et al. Treatment of refractory giant cell arteritis with cyclophosphamide: a retrospective analysis of 35 patients from three centres. Clin Exp Rheumatol 2012; 30: S70-S76.
• 46. Quartuccio L, Maset M, De Maglio G, et al. Role of oral cyclophosphamide in the treatment of giant cell arteritis. Rheumatology (Oxford) 2012; 51: 1677-86.
• 47. Henes JC, Mueller M, Pfannenberg C, et al. Cyclophosphamide for large vessel vasculitis: assessment of response by PET/CT. Clin Exp Rheumatol 2011; 29: S43-48.
• 48. Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007; 146: 621-30.
• 49. Osman M, Pagnoux C, Dryden DM, et al. The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis. PLoS One 2014; 9: e115026.
• 50. Sciascia S, Rossi D, Roccatello D. Interleukin 6 blockade as steroid- -sparing treatment for 2 patients with giant cell arteritis. J Rheumatol 2011; 38: 2080-1.
• 51. Stone JH, Tuckwell K, Dimonaco S, et al. Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, PlaceboControlled Trial [abstract]. Arthritis Rheumatol 2016; 68 (suppl 10).
• 52. Adler S, Reichenbach S, Kuchen S, et al. Termination of Tocilizumab- -Treatment in Giant Cell Arteritis: Follow-up of Patients after the RCT [abstract]. Arthritis Rheumatol 2016; 68 (suppl 10).
• 53. Langford CA, Cuthbertson D, Ytterberg SR, et al. A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. Arthritis Rheumatol 2017; 69: 837-45.
• 54. Langford CA, Cuthbertson D, Ytterberg SR, et al. A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis. Arthritis Rheumatol 2017; 69: 846-53.
• 55. Weyand CM, Liao YJ, Goronzy JJ. The immunopathology of giant cell arteritis: diagnostic and therapeutic implications. J Neuroophthalmol 2012; 32: 259-65.
• 56. Hamrin B. Polymyalgia arteritica. Acta Med Scand Suppl 1972; 533: 1-131.

• Document Type: article